1. In a patient with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease (ASCVD), the two evidence-based add-on classes are glucagon-like peptide-1 receptor (GLP-1R) agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors. Which statement correctly distinguishes their dominant cardiovascular benefit?
A) Both classes reduce non-fatal stroke as their single dominant endpoint
B) GLP-1R agonists reduce heart failure hospitalization as their dominant endpoint, while SGLT-2 inhibitors reduce non-fatal stroke
C) GLP-1R agonists reduce atherosclerotic events (non-fatal myocardial infarction and stroke), while SGLT-2 inhibitors reduce cardiovascular death and heart failure hospitalization
D) Both classes act primarily by lowering HbA1c, with no event-specific difference between them
GLP-1R agonists have the strongest evidence for reducing the atherosclerotic endpoint of non-fatal myocardial infarction (MI) and stroke, whereas SGLT-2 inhibitors predominantly reduce cardiovascular death and heart failure hospitalization through a hemodynamic mechanism. This complementary split is the basis for combining the two classes.
Option A: Option A is incorrect because only GLP-1R agonists have a strong stroke-reduction signal; SGLT-2 inhibitors do not.
Option B: Option B inverts the two classes and is incorrect.
Option D: Option D is incorrect because the cardiovascular benefits of both classes are largely independent of glycemic lowering.
Option E: Option E inverts the endpoints, attributing the atherosclerotic benefit to SGLT-2 inhibitors and the heart failure benefit to GLP-1R agonists, which is incorrect.
2. The ADA distinguishes patients with "established ASCVD" from those with "multiple risk factors but no prior event." Which definition correctly identifies established ASCVD?
A) A documented prior atherosclerotic event such as myocardial infarction, unstable angina requiring hospitalization, coronary revascularization, ischemic stroke or transient ischemic attack, or hemodynamically significant peripheral arterial disease
B) The presence of two or more risk factors such as hypertension, dyslipidemia, and smoking, without any prior event
C) An elevated coronary artery calcium score in an asymptomatic patient
D) A family history of premature coronary disease in a first-degree relative
E) An HbA1c above 9% indicating poorly controlled diabetes
ANSWER: A
Rationale:
Established ASCVD is defined by a documented prior atherosclerotic event: myocardial infarction, unstable angina requiring hospitalization, coronary revascularization, ischemic stroke or transient ischemic attack, or hemodynamically significant peripheral arterial disease.
Option B: Option B describes the high-risk-but-not-established category, where atherosclerotic event-reduction evidence is weaker.
Option C: Option C is incorrect because an imaging finding without a clinical event does not constitute established ASCVD.
Option D: Option D is incorrect because family history alone is a risk factor, not an established event.
Option E: Option E is incorrect because glycemic control reflects diabetes severity, not the presence of established atherosclerotic disease.
3. A clinician must recall the estimated glomerular filtration rate (eGFR) thresholds that govern metformin use in chronic kidney disease (CKD). Which statement is correct?
A) Metformin should be stopped once eGFR falls below 60 mL per minute per 1.73 m squared
B) Metformin may be continued without dose change at any eGFR
C) Metformin should be stopped once eGFR falls below 45 mL per minute per 1.73 m squared
D) Metformin may be continued down to an eGFR of 30 mL per minute per 1.73 m squared, with dose reduction recommended below 45
E) Metformin should be reduced only once eGFR falls below 15 mL per minute per 1.73 m squared
ANSWER: D
Rationale:
The consensus thresholds for metformin are continuation down to an eGFR of 30 mL per minute per 1.73 m squared, with dose reduction recommended below 45; this reflects the risk of metformin accumulation and lactic acidosis in advanced renal impairment.
Option A: Option A is incorrect because continuation is supported well below an eGFR of 60.
Option B: Option B is incorrect because metformin clearance is renally dependent and the dose must be adjusted as eGFR declines.
Option C: Option C is incorrect because 45 is the dose-reduction threshold, not the discontinuation threshold; metformin may continue to 30.
Option E: Option E is incorrect because action is required at 45 and 30, not deferred until 15.
4. SGLT-2 inhibitors lower intraglomerular pressure as part of their nephroprotective effect. Which mechanism correctly describes how they do so?
A) Dilation of the efferent arteriole, reducing downstream resistance
B) Constriction of the afferent arteriole through tubuloglomerular feedback, lowering intraglomerular pressure
C) Direct inhibition of renin release from the juxtaglomerular apparatus
D) Blockade of the mineralocorticoid receptor in the distal nephron
E) Inhibition of angiotensin-converting enzyme in the renal vasculature
ANSWER: B
Rationale:
SGLT-2 inhibition increases sodium delivery to the macula densa, which through tubuloglomerular feedback constricts the afferent arteriole and lowers intraglomerular pressure.
Option A: Option A is incorrect because efferent dilation is the mechanism of renin-angiotensin-aldosterone system (RAAS) blockade, not SGLT-2 inhibition.
Option C: Option C is incorrect because SGLT-2 inhibitors do not act by directly inhibiting renin release.
Option D: Option D describes mineralocorticoid receptor antagonists such as finerenone, not SGLT-2 inhibitors.
Option E: Option E describes angiotensin-converting enzyme inhibitors, a form of RAAS blockade, not the SGLT-2 mechanism.
5. Renin-angiotensin-aldosterone system (RAAS) blockade with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) is a pillar of diabetic kidney disease management. By what hemodynamic mechanism does RAAS blockade reduce intraglomerular pressure?
A) Constriction of the afferent arteriole via tubuloglomerular feedback
B) Increased sodium reabsorption that expands plasma volume
C) Direct constriction of both afferent and efferent arterioles
D) Inhibition of sodium-glucose cotransport in the proximal tubule
E) Dilation of the efferent arteriole, which lowers intraglomerular pressure and slows albuminuria progression
ANSWER: E
Rationale:
RAAS blockade reduces intraglomerular pressure primarily by dilating the efferent arteriole, which lowers glomerular capillary pressure and slows albuminuria progression.
Option A: Option A is incorrect because afferent constriction via tubuloglomerular feedback is the SGLT-2 inhibitor mechanism.
Option B: Option B is incorrect because RAAS blockade reduces, rather than increases, sodium reabsorption and volume.
Option C: Option C is incorrect because the dominant action is efferent dilation, not constriction of both arterioles.
Option D: Option D describes the SGLT-2 inhibitor mechanism in the proximal tubule, not RAAS blockade.
6. Finerenone is used for diabetic kidney disease on a background of RAAS blockade. To which drug class does finerenone belong?
A) Sodium-glucose cotransporter 2 (SGLT-2) inhibitor
B) Angiotensin receptor blocker (ARB)
C) Non-steroidal mineralocorticoid receptor antagonist (MRA)
Finerenone is a non-steroidal mineralocorticoid receptor antagonist, distinguished from steroidal MRAs such as spironolactone by a more favorable hyperkalemia profile, and it is added on top of RAAS blockade in diabetic kidney disease.
Option A: Option A is incorrect because finerenone is not an SGLT-2 inhibitor and does not act through afferent arteriolar feedback.
Option B: Option B is incorrect because it is not an ARB; it blocks the mineralocorticoid receptor rather than the angiotensin II receptor.
Option D: Option D is incorrect because it is not a DPP-4 inhibitor and has no incretin activity.
Option E: Option E is incorrect because it is not a GLP-1R agonist.
7. Among the dipeptidyl peptidase-4 (DPP-4) inhibitors, the need for renal dose adjustment differs by agent. Which DPP-4 inhibitor requires no dose adjustment for renal impairment and is appropriate even in advanced CKD?
A) Linagliptin
B) Sitagliptin
C) Alogliptin
D) Saxagliptin
E) Vildagliptin
ANSWER: A
Rationale:
Linagliptin requires no dose adjustment for renal impairment and is appropriate even in advanced CKD and dialysis because it is not predominantly renally cleared.
Option B: Option B is incorrect because sitagliptin requires dose reduction as eGFR falls.
Option C: Option C is incorrect because alogliptin also requires renal dose reduction.
Option D: Option D is incorrect because saxagliptin requires dose adjustment in renal impairment and additionally carries a heart failure hospitalization signal.
Option E: Option E is incorrect because vildagliptin requires dose adjustment in moderate to severe renal impairment.
8. A patient with declining renal function is taking a DPP-4 inhibitor. The clinician needs to recall which agents require downward dose adjustment as eGFR falls. Which statement is correct?
A) No DPP-4 inhibitor requires renal dose adjustment
B) Only linagliptin requires renal dose adjustment
C) All DPP-4 inhibitors must be discontinued once eGFR falls below 45
D) Sitagliptin and alogliptin require dose reduction as eGFR falls, whereas linagliptin does not
E) DPP-4 inhibitors require dose increases as renal function declines to maintain efficacy
ANSWER: D
Rationale:
Sitagliptin and alogliptin are predominantly renally cleared and require dose reduction as eGFR falls, whereas linagliptin requires no renal dose adjustment.
Option A: Option A is incorrect because several agents in the class do require adjustment.
Option B: Option B is incorrect because linagliptin is the agent that does NOT require adjustment, the opposite of the claim.
Option C: Option C is incorrect because the class is not uniformly discontinued at eGFR 45; agents are dose-adjusted and linagliptin continues unchanged.
Option E: Option E is incorrect because renal impairment calls for dose reduction of the renally cleared agents, not dose escalation.
9. Heart failure is categorized by left ventricular ejection fraction (LVEF). Which definition correctly identifies heart failure with reduced ejection fraction (HFrEF)?
A) LVEF above 50%
B) LVEF at or below 40%
C) LVEF between 41% and 49% only
D) Any LVEF in the presence of symptoms, regardless of value
E) LVEF above 40% with preserved filling pressures
ANSWER: B
Rationale:
Heart failure with reduced ejection fraction is defined as an LVEF at or below 40%, the category in which dapagliflozin and empagliflozin demonstrated reductions in cardiovascular death or heart failure hospitalization.
Option A: Option A is incorrect because an LVEF above 50% is in the preserved range.
Option C: Option C describes the mildly-reduced ejection fraction range, not HFrEF.
Option D: Option D is incorrect because the classification depends on the measured ejection fraction, not symptoms alone.
Option E: Option E describes heart failure with preserved ejection fraction (HFpEF), not HFrEF.
10. Thiazolidinediones (TZDs) carry a specific heart failure restriction. Which statement correctly pairs the restriction with its mechanism?
A) Contraindicated in all heart failure because of direct negative inotropy
B) Safe in all NYHA classes because they reduce afterload
C) Contraindicated in New York Heart Association (NYHA) class III or IV heart failure because peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation promotes sodium and water retention, worsening fluid overload
D) Contraindicated only in heart failure with preserved ejection fraction due to diastolic stiffening
E) Restricted only because they cause euglycemic diabetic ketoacidosis
ANSWER: C
Rationale:
Thiazolidinediones are contraindicated in NYHA class III or IV heart failure because PPAR-gamma activation in the collecting duct promotes sodium and water retention, exacerbating fluid overload and increasing heart failure hospitalization.
Option A: Option A is incorrect because the mechanism is fluid retention, not direct negative inotropy, and the contraindication is class-specific.
Option B: Option B is incorrect because TZDs are not safe across all NYHA classes; they worsen fluid overload.
Option D: Option D is incorrect because the contraindication relates to advanced symptomatic heart failure (class III–IV), not specifically to preserved ejection fraction.
Option E: Option E is incorrect because euglycemic diabetic ketoacidosis is an SGLT-2 inhibitor risk, not the basis for the TZD heart failure restriction.
11. Within the DPP-4 inhibitor class, one agent is specifically associated with increased heart failure hospitalization and should be avoided in patients with established or high-risk heart failure. Which agent is it?
A) Sitagliptin
B) Linagliptin
C) Metformin
D) Empagliflozin
E) Saxagliptin
ANSWER: E
Rationale:
Saxagliptin was associated with increased heart failure hospitalization and should be avoided in patients with established or high-risk heart failure; this is not a class-wide effect.
Option A: Option A is incorrect because sitagliptin demonstrated neutral heart failure outcomes.
Option B: Option B is incorrect because linagliptin also demonstrated neutral heart failure outcomes.
Option C: Option C is incorrect because metformin is a biguanide, not a DPP-4 inhibitor, and is not associated with heart failure risk.
Option D: Option D is incorrect because empagliflozin is an SGLT-2 inhibitor that reduces heart failure hospitalization rather than increasing it.
12. SGLT-2 inhibitors are held during acute decompensated heart failure hospitalization in the fasting, fluid-restricted patient. Which adverse condition is the principal metabolic reason for holding them in this setting?
A) Hyperglycemic hyperosmolar state
B) Lactic acidosis from impaired lactate clearance
C) Euglycemic diabetic ketoacidosis, in which ketoacidosis occurs without marked hyperglycemia
D) Hypoglycemic coma from excess insulin secretion
E) Respiratory alkalosis from compensatory hyperventilation
ANSWER: C
Rationale:
SGLT-2 inhibitors can precipitate euglycemic diabetic ketoacidosis, in which ketoacidosis develops without the marked hyperglycemia that usually signals diabetic ketoacidosis; the fasting, fluid-restricted state of acute decompensated heart failure heightens this risk, which is why the drug is held.
Option A: Option A is incorrect because hyperglycemic hyperosmolar state is not the characteristic SGLT-2 inhibitor risk and features very high glucose.
Option B: Option B is incorrect because lactic acidosis is a metformin-associated risk.
Option D: Option D is incorrect because SGLT-2 inhibitors do not stimulate insulin secretion or cause hypoglycemic coma.
Option E: Option E is incorrect because respiratory alkalosis is not the metabolic complication driving the recommendation to hold these agents.
13. Insulin is the pharmacological standard of care for diabetes in pregnancy. Which property best explains why insulin holds this status?
A) It is the agent with long-term pregnancy safety data and offers dose-titratable precision, and it is the regulatory standard of care
B) It is the only agent that does not cross the placenta in any amount
C) It is the least expensive option and therefore preferred on cost grounds
D) It uniquely suppresses placental hormone production that drives insulin resistance
E) It is preferred because it requires the fewest daily administrations
ANSWER: A
Rationale:
Insulin is the standard of care in pregnancy because it has long-term pregnancy safety data, allows dose-titratable precision, and is the regulatory standard, while most non-insulin agents lack adequate human pregnancy safety data.
Option B: Option B is incorrect because insulin's status is based on its safety and titratability, not a claim of zero placental transfer.
Option C: Option C is incorrect because cost is not the basis for its preferred status.
Option D: Option D is incorrect because insulin does not suppress the placental hormones that drive gestational insulin resistance.
Option E: Option E is incorrect because the rationale is safety and titratability, not administration frequency.
14. SGLT-2 inhibitors carry a specific pregnancy restriction. Which statement correctly describes it and the underlying concern?
A) They are safe throughout pregnancy because they are not absorbed systemically
B) They are contraindicated in the second and third trimesters because the glucosuria-altered fetal urinary environment raises concern for fetal renal development, and labeling advises discontinuation when pregnancy is recognized
C) They are restricted only in the first trimester due to neural tube defect risk
D) They are preferred in pregnancy because of their renoprotective effects
E) They are contraindicated only during breastfeeding, not during pregnancy
ANSWER: B
Rationale:
SGLT-2 inhibitors are contraindicated in the second and third trimesters because the glucosuria they induce alters the fetal urinary glucose environment during critical periods of fetal renal development, and labeling advises discontinuation when pregnancy is recognized.
Option A: Option A is incorrect because SGLT-2 inhibitors are systemically active and are not safe throughout pregnancy.
Option C: Option C is incorrect because the principal concern relates to second- and third-trimester fetal renal development, not first-trimester neural tube defects.
Option D: Option D is incorrect because renoprotection in nonpregnant patients does not make them preferred in pregnancy, where they are contraindicated.
Option E: Option E is incorrect because the restriction applies during pregnancy, not solely during breastfeeding.
15. The American Geriatrics Society Beers Criteria flag a specific sulfonylurea as potentially inappropriate in adults over 65. Which agent is flagged, and why?
A) Glipizide, because it has the longest half-life of all sulfonylureas
B) Metformin, because it accumulates and causes hypoglycemia in the elderly
C) Linagliptin, because its renal clearance is unpredictable in older adults
D) Glibenclamide (glyburide), because its prolonged duration of action increases the risk of severe hypoglycemia in older adults
E) Sitagliptin, because it has a high risk of causing severe hypoglycemia as monotherapy
ANSWER: D
Rationale:
The Beers Criteria flag glibenclamide (glyburide) as potentially inappropriate in adults over 65 because its prolonged duration of action increases the risk of severe hypoglycemia.
Option A: Option A is incorrect because glipizide is shorter-acting than glibenclamide and is not the specifically flagged agent.
Option B: Option B is incorrect because metformin does not cause hypoglycemia and is generally acceptable in older adults with preserved renal function.
Option C: Option C is incorrect because linagliptin is well tolerated in the elderly and requires no renal dose adjustment.
Option E: Option E is incorrect because sitagliptin, as a DPP-4 inhibitor, has minimal hypoglycemia risk as monotherapy.
16. A patient with pre-existing diabetes managed with insulin during pregnancy has just delivered. In which direction do insulin requirements change in the immediate postpartum period, and why?
A) They rise sharply because lactation increases glucose demand
B) They remain unchanged because placental hormone effects persist for weeks
C) They rise gradually over the first month as metabolism normalizes
D) They are unpredictable and unrelated to delivery timing
E) They fall sharply within hours of placental delivery because the placental hormones that drove insulin resistance are withdrawn, requiring prompt dose reduction
ANSWER: E
Rationale:
Insulin requirements fall sharply within hours of placental delivery because the placental hormones (human placental lactogen, cortisol, progesterone, prolactin) that drove second- and third-trimester insulin resistance are abruptly withdrawn, so the insulin dose must be reduced promptly to avoid postpartum hypoglycemia.
Option A: Option A is incorrect because requirements fall rather than rise after delivery.
Option B: Option B is incorrect because placental hormone effects do not persist for weeks; they resolve rapidly once the placenta is delivered.
Option C: Option C is incorrect because the change is rapid (within hours), not a gradual month-long decline.
Option D: Option D is incorrect because the change is predictable and directly tied to placental delivery.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.